Statistics from Altmetric.com
Question: Does atomoxetine reduce symptoms of attention deficit/hyperactivity (ADHD) disorder in children with autism spectrum disorder (ASD) compared with placebo?
Patients: Ninety-seven children and adolescents aged between 6 and 17 years with a clinical diagnosis of ASD (confirmed using the Autism Diagnostic Interview revised) and concomitant ADHD symptoms (according to DSM-IV-TR criteria, confirmed using the ADHD Rating Scale, ADHD-RS). Exclusions: psychosis, bipolar disorder, substance abuse, serious medical illness, previous seizures, current use of psychoactive medications other than the study medication, intended start of inpatient treatment or structured psychotherapy, or weight <20 kg.
Setting: Nine child and adolescent psychiatry centres and other mental health institutions, the Netherlands; time period not stated.
Intervention: 1.2 mg/kg/day atomoxetine versus placebo for 8 weeks. Atomoxetine dose was titrated up to the fixed once-daily dose over 3 weeks (0.5 mg/kg/day first week, 0.8 mg/kg/day second week, 1.2 mg/kg/day third and subsequent weeks). Individuals who started inpatient treatment, structured psychotherapy or other psychoactive medications were discontinued from the study.
Outcomes: Primary outcome: change in ADHD-RS …
Sources of funding Eli Lilly and Co.
▸ References are published online only. To view this file please visit the journal online (http://dx.doi.org/10.1136/eb-2012-100967).
Competing interests None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.